Phase II Trial of Maintenance Apatinib After Second-Line Treatment for Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 May 2018
At a glance
- Drugs Rivoceranib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 10 May 2018 Planned End Date changed from 30 Dec 2019 to 8 Dec 2019.
- 10 May 2018 Planned primary completion date changed from 30 Dec 2018 to 8 Apr 2019.
- 10 May 2018 Status changed from recruiting to active, no longer recruiting.